More News and Clinical Research about Emerging Approaches in Schizophrenia

JCP
Sulforaphane Added to Antipsychotics for Negative Symptoms of Schizophrenia
Original Research

January 20, 2025

Add-on high dose sulforaphane may reduce negative symptoms in patients with schizophrenia, although the clinical significance of this reduction needs further evaluation.
, , , et al
Gut Microbiome Breakthroughs Revolutionize Schizophrenia Treatment
news

January 15, 2025

A growing body of research has revealed a link between the gut microbiome and mental disorders, such as treatment-resistant schizophrenia.
JCP
Olanzapine/Samidorphan Effects on Weight Gain
Original Research

January 2, 2025

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over…
, , , et al
Unified Brain Network Links Schizophrenia Atrophy
news

December 12, 2024

Researchers identified a brain network tied to schizophrenia, allowing for earlier detection and targeted treatments.
Could Intermittent Theta Burst Stimulation Treat Schizophrenia?
news

December 3, 2024

Intermittent theta burst stimulation (iTBS) over the left dorsolateral prefrontal cortex shows promise as a schizophrenia treatment.
Divergent Perspectives Threaten Schizophrenia Treatment
news

November 5, 2024

The main challenges in treating schizophrenia arise from differing perceptions of antipsychotic side effects between patients and physicians.
Exploring the Link Between Schizophrenia and Alzheimer’s 
news

November 1, 2024

Research reveals shared cholinergic pathway dysfunction in schizophrenia and Alzheimer’s, leading to a new FDA-approved treatment.
Understanding Neurotransmitters in Schizophrenia Beyond Dopamine
news

October 30, 2024

Research has revealed that multiple neurotransmitters contribute to schizophrenia, suggesting the potential for non-dopaminergic therapies.
Cholinergic Neurotransmission’s Role in Schizophrenia Symptoms
news

October 28, 2024

Cholinergic neurotransmission, an overlooked target in schizophrenia, influences brain functions, offering an alternative to antipsychotics.
Managing Weight, Metabolic Syndrome, and Diabetes in Schizophrenia Patients
news

October 17, 2024

Managing weight gain, metabolic syndrome, and diabetes in schizophrenia patients demands attention to side effects and lifestyle factors.
The History of Dopaminergic Blockade in Schizophrenia
news

October 4, 2024

Schizophrenia remains a debilitating condition that’s prompted the development of both dopamine-based and emerging non-dopaminergic therapies.
Beyond Dopamine: Evaluating the Pipeline for Schizophrenia
news

October 4, 2024

New schizophrenia drugs targeting non-dopaminergic pathways show promise in overcoming the limitations of existing therapies.

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe